Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-19

FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc. The product is a ustekinumab biosimilar, and the app…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SELARSDI (USTEKINUMAB-AEKN)

Snippet

SUPPL AP for SELARSDI (USTEKINUMAB-AEKN)